Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Sees Significant Increase in Short Interest

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,820,000 shares, an increase of 6.4% from the October 31st total of 3,590,000 shares. Based on an average daily trading volume, of 707,100 shares, the short-interest ratio is currently 5.4 days. Approximately 6.6% of the company’s shares are sold short.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $123.45 on Thursday. The firm has a 50-day moving average price of $115.69 and a 200 day moving average price of $111.38. The firm has a market capitalization of $7.46 billion, a PE ratio of 17.39, a P/E/G ratio of 1.03 and a beta of 0.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research analyst reports. Piper Sandler reissued an “overweight” rating and set a $163.00 price objective (down from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Finally, TD Cowen cut their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $175.33.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,163 shares of company stock worth $968,992. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Swedbank AB acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $106,936,000. Rubric Capital Management LP bought a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at $65,812,000. Pacer Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after purchasing an additional 527,187 shares in the last quarter. Baupost Group LLC MA lifted its position in Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after buying an additional 440,552 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after buying an additional 427,246 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.